Recombinant Human Anti-CD3 x Human Anti-VEGFR1 Bispecific Antibody (Minibody) (MiniB-H284)

Recombinant Anti-CD3 x Anti-VEGFR1 Bispecific Antibody (Minibody) is designed to be expressed as the anti-CD3 scFv fused to N-terminus of Knob-CH3 domain and the anti-VEGFR1 scFv to the Hole-CH3 domain, or vice versa. The CH3 domains are further stabilized by C-terminal disulfide bonds. This BsAb can retarget T cells to tumor cells. It is designed for the research of Colon cancer; Rectal cancer therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & VEGFR1

Type

Minibody

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Colon cancer; Rectal cancer

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

VEGFR1

Gene ID

2321

UniProt ID

P17948

Alternative Names

FLT1; fms-related tyrosine kinase 1; FLT; FLT-1; VEGFR1; VEGFR-1; vascular endothelial growth factor receptor 1; fms-like tyrosine kinase 1; tyrosine-protein kinase FRT; tyrosine-protein kinase receptor FLT; vascular permeability factor receptor; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD3 x Human Anti-VEGFR1 Bispecific Antibody (Minibody) (MiniB-H284). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD3 x Human Anti-VEGFR1 Bispecific Antibody (Minibody) (CAT#: MiniB-H284)

Specifications

Targets

Customer Reviews and Q&As